Clinical trial
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
NCT03420963 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 31, 2018
- Completion date
- February 26, 2026
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent cutaneous melanoma, recurrent lip and oral cavity carcinoma, recurrent malignant endocrine neoplasm, recurrent malignant female reproductive system neoplasm, recurrent malignant male reproductive system neoplasm, recurrent malignant mesothelioma, recurrent malignant neoplasm of multiple primary sites, recurrent malignant oral neoplasm, recurrent malignant pharyngeal neoplasm, recurrent malignant skin neoplasm, recurrent malignant soft tissue neoplasm, recurrent malignant solid neoplasm, recurrent malignant thyroid gland neoplasm, recurrent malignant urinary system neoplasm, refractory cutaneous melanoma, refractory malignant bone neoplasm, refractory malignant endocrine neoplasm, refractory malignant female reproductive system neoplasm, refractory malignant male reproductive system neoplasm, refractory malignant mesothelioma, refractory malignant neoplasm of multiple primary sites, refractory malignant oral neoplasm, refractory malignant pharyngeal neoplasm, refractory malignant skin neoplasm, refractory malignant soft tissue neoplasm, refractory malignant solid neoplasm, refractory malignant thyroid gland neoplasm, refractory malignant urinary system neoplasm